McKesson's FY2026: Record Revenue, Growth, & Spin-off

McKessons fiscal year 2026 ended with impressive results, including a 12% revenue increase to $403 billion and an 18% rise in adjusted earnings per share to $39.11. The companys operating cash flow reached $6.2 billion, surpassing expectations, and returned $5.1 billion to shareholders through buybacks and dividends. Growth was driven by strong performances in oncology, multispecialty, and biopharma platforms. McKesson successfully integrated acquisitions like Core Ventures and PRISM Vision, enhancing community care and adding hundreds of providers to the U.S. Oncology Network. The company also made significant portfolio moves, fully exiting Norway and advancing the Medical-Surgical Solutions spin-off with a $1 billion term loan, revolving credit, and Apollos $1.25 billion minority stake for a 13% ownership, valuing it at $13 billion. Leadership, including retiring CFO Britt Vitalone and new Chairman Brian Tyler, received recognition for delivering over 500% shareholder returns. The companys I2CARE values and LEADRx principles kept employees engaged, enabling them to navigate weather disruptions and Inflation Reduction Act price shifts. For fiscal 2027, McKesson is guiding adjusted earnings per share to $43.80 to $44.60, representing a 12% to 14% growth. Oncology revenue is expected to rise by 14.5% to 18.5%, and biopharma is set to reach new records with 3.4 million patients served. The new AI-powered Montreal center will also boost supply chain efficiency. McKesson enters the new year with a lean, tech-forward, and cash-rich approach, poised to scale specialty meds, support providers, and unlock value from the split while continuing to reward shareholders. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/688387eef6474130